Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | The anti-leukemic potential of CD1c-restricted T cells

Michela Consonni, PhD, San Raffaele Scientific Institute, Millan, Italy, gives an overview of newly identified methyl-lysophosphatidic acids (mLPAs) that are highly expressed in leukemia cells and are presented by CD1c, a monomorphic major histocompatibility complex (MHC) class I-like molecule. CD1c-restricted T lymphocytes have found to target CD1c+ leukemia cells and Dr Consonni highlights the advantages of these lipid-specific T cells as an alternative to existing T-cell therapies, including the lower risk of graft versus host disease (GvHD) as a result of CD1c being solely expressed in hematopoietic cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.